Trials / Completed
CompletedNCT00188929
Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma
Spatio-temporal Response of Non-Hodgkin's Lymphoma to External Beam Radiation Therapy Measuring 18F-Fluorodeoxyglucose (FDG) Uptake Using a Combined PET/CT Scanner: A Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study the treatment process will be closely monitored using a novel imaging technology, a PET/CT scanner. PET stands for Positron Emission Tomography and in this case it will be combined with a conventional x-ray Computerized Tomography (CT) scan. This is not a study of any particular form of treatment. The treatment you receive will be the most appropriate standard treatment whether you are in the study or not. The goal of radiation therapy is to deliver a given amount of radiation dose to the area where there is a lymphoma tumour. We are doing this study to see which part of the tumour reacts to the radiation treatment, and which part does not react, by monitoring the progress of your treatment with a combined PET/CT scan. In particular, changes of the size and shape of the tumour that occur during the treatment can be detected and will be visible on the images. These images will be thoroughly analysed. The ability of the PET/CT scanner to detect these changes during a course of radiation treatment will be the subject of this study. We will also be able to see if this information will eventually relate to or predict whether lymphoma tumours will be completely eradicated by the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | PET Scan with [18F]Fluoro-2-deoxyglucose (FDG) |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2005-09-16
- Last updated
- 2010-08-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00188929. Inclusion in this directory is not an endorsement.